These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 2109379)

  • 21. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OKT3-associated adverse reactions: mechanistic basis and therapeutic options.
    Suthanthiran M; Fotino M; Riggio RR; Cheigh JS; Stenzel KH
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):39-44. PubMed ID: 2530898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reduction of TNF-alpha release and clinical effects of the first injection of OKT3].
    Meulders Q; Dallel T; Peraldi MN; Kanfer A; Sraer JD; Rondeau E
    Presse Med; 1992 Dec; 21(41):2024-6. PubMed ID: 1294974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment.
    Zlabinger GJ; Stuhlmeier KM; Eher R; Schmaldienst S; Klauser R; Vychytil A; Watschinger B; Traindl O; Kovarik J; Pohanka E
    J Clin Immunol; 1992 May; 12(3):170-7. PubMed ID: 1400897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.
    Vasquez EM; Pollak R
    Clin Transplant; 1996 Jun; 10(3):294-7. PubMed ID: 8826669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3.
    Bemelman FJ; Buysmann S; Surachno J; Wilmink JM; Schellekens PT; ten Berge IJ
    Kidney Int; 1994 Dec; 46(6):1674-9. PubMed ID: 7700026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
    Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
    Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.
    Ferran C; Sheehan K; Dy M; Schreiber R; Merite S; Landais P; Noel LH; Grau G; Bluestone J; Bach JF
    Eur J Immunol; 1990 Mar; 20(3):509-15. PubMed ID: 2138557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis.
    Horneff G; Krause A; Emmrich F; Kalden JR; Burmester GR
    Cytokine; 1991 May; 3(3):266-7. PubMed ID: 1909192
    [No Abstract]   [Full Text] [Related]  

  • 32. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
    Herold KC; Burton JB; Francois F; Poumian-Ruiz E; Glandt M; Bluestone JA
    J Clin Invest; 2003 Feb; 111(3):409-18. PubMed ID: 12569167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10.
    Donckier V; Flament V; Gérard C; Abramowicz D; Vandenabeele P; Wissing M; Delvaux A; Fiers W; Leo O; Velu T
    Transplantation; 1994 May; 57(10):1436-9. PubMed ID: 8197603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis.
    Attisano C; Bianchi A; Montacchini L; Carlesso N; Peola S; Bruno B; Roux V; Ferrero D; Gallo E; Boccadoro M
    Br J Haematol; 1994 Jul; 87(3):494-502. PubMed ID: 7993789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
    Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
    Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic response to OKT3 in orthotopic heart transplant recipients: evidence for reversible myocardial dysfunction.
    Breisblatt WM; Schulman DS; Stein K; Wolfe CJ; Whiteside T; Kormos R; Hardesty RL
    J Heart Lung Transplant; 1991; 10(3):359-65. PubMed ID: 1906745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunoneutralization of interleukin-1, tumor necrosis factor, interleukin-6 or interferon does not prevent the LPS-induced sick euthyroid syndrome in mice.
    Boelen A; Platvoet-ter Schiphorst MC; Wiersinga WM
    J Endocrinol; 1997 Apr; 153(1):115-22. PubMed ID: 9135576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.